Hyperthyroidism News and Research

RSS
Hyperthyroidism is a disorder that occurs when the thyroid gland makes more thyroid hormone than the body needs. It is sometimes called thyrotoxicosis, the technical term for too much thyroid hormone in the blood. About 1 percent of the U.S. population has hyperthyroidism. Women are much more likely to develop hyperthyroidism than men.
Positive results from Shire's Vyvanse clinical trial in schizophrenia

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

New ATA recommendations on outpatient 131I therapy aim to treat thyroid cancer

New ATA recommendations on outpatient 131I therapy aim to treat thyroid cancer

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

BMY receives FDA approval for YERVOY to treat metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Experts issue joint statement to help Americans understand radiation-related health risks

Experts issue joint statement to help Americans understand radiation-related health risks

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Research may lead to new treatment strategies for Graves' disease

Research may lead to new treatment strategies for Graves' disease

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

UCI first medical center on West Coast to perform robotic thyroidectomies

UCI first medical center on West Coast to perform robotic thyroidectomies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.